COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
23 06 2021
23 06 2021
Historique:
received:
14
01
2021
accepted:
01
06
2021
entrez:
24
6
2021
pubmed:
25
6
2021
medline:
20
7
2021
Statut:
epublish
Résumé
While mass-scale vaccination campaigns are ongoing worldwide, genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to monitor the emergence and global spread of viral variants of concern (VOC). Here, we present a streamlined workflow-COVseq-which can be used to generate highly multiplexed sequencing libraries compatible with Illumina platforms from hundreds of SARS-CoV-2 samples in parallel, in a rapid and cost-effective manner. We benchmark COVseq against a standard library preparation method (NEBNext) on 29 SARS-CoV-2 positive samples, reaching 95.4% of concordance between single-nucleotide variants detected by both methods. Application of COVseq to 245 additional SARS-CoV-2 positive samples demonstrates the ability of the method to reliably detect emergent VOC as well as its compatibility with downstream phylogenetic analyses. A cost analysis shows that COVseq could be used to sequence thousands of samples at less than 15 USD per sample, including library preparation and sequencing costs. We conclude that COVseq is a versatile and scalable method that is immediately applicable for SARS-CoV-2 genomic surveillance and easily adaptable to other pathogens such as influenza viruses.
Identifiants
pubmed: 34162869
doi: 10.1038/s41467-021-24078-9
pii: 10.1038/s41467-021-24078-9
pmc: PMC8222401
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3903Références
Science. 2021 Jan 8;371(6525):172-177
pubmed: 33172935
Genome Med. 2020 Jun 30;12(1):57
pubmed: 32605661
Nat Biotechnol. 2020 Mar;38(3):276-278
pubmed: 32055031
Nat Commun. 2019 Oct 18;10(1):4732
pubmed: 31628304
Genes (Basel). 2020 Aug 17;11(8):
pubmed: 32824573
N Engl J Med. 2021 May 13;384(19):1866-1868
pubmed: 33761203
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
F1000Res. 2018 Aug 24;7:1338
pubmed: 30254741
Emerg Infect Dis. 2020 Oct;26(10):2401-2405
pubmed: 32610037
Brief Bioinform. 2021 Mar 22;22(2):616-630
pubmed: 33279989
Front Microbiol. 2020 Jul 22;11:1800
pubmed: 32793182
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Curr Protoc Bioinformatics. 2020 Mar;69(1):e96
pubmed: 32162851
Lancet Infect Dis. 2020 Nov;20(11):1263-1271
pubmed: 32679081
Nature. 2021 Jan;589(7842):337-338
pubmed: 33452508
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Nat Biotechnol. 2017 Apr 11;35(4):316-319
pubmed: 28398311
Mol Cell. 2020 Dec 17;80(6):1123-1134.e4
pubmed: 33290743
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Viruses. 2020 Aug 15;12(8):
pubmed: 32824272
Clin Chem. 2020 Nov 1;66(11):1450-1458
pubmed: 32715310
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Genome Biol. 2019 Jan 8;20(1):8
pubmed: 30621750